Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...
Chronic pain care is shifting to indication-specific, non-opioid therapies, creating opportunities for durable treatments, precision tools and integrated care for aging populations.Dublin, Sept. 17, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results